Sign in Subscribe
Pharmaceutical industry

Corgentech Appoints Richard B. Brewer to Board of Directors

Strategic Insights

— 1 min read

Richard B. Brewer, a seasoned executive with nearly 30 years of biopharmaceutical industry experience, has been appointed to the board of directors at Corgentech, Inc. Brewer's background and expertise include building companies and commercializing products, particularly in the cardiovascular and pharmaceutical sectors. He brings a wealth of knowledge and experience to Corgentech, which is currently developing E2F Decoy (edifoligide sodium), a product candidate that has shown promise in preventing bypass graft failure following coronary artery bypass graft (CABG) and peripheral bypass graft surgery.

Key Takeaways:

  • Richard B. Brewer has been appointed to the board of directors at Corgentech, Inc., a biotechnology company developing E2F Decoy, a product candidate for preventing bypass graft failure.
  • Brewer brings nearly 30 years of biopharmaceutical industry experience to Corgentech, including his role as the founding partner of Crest Asset Management, where he provides management counsel to healthcare and biotechnology companies.
  • He previously served as the chief executive officer and president of Scios, Inc., a biopharmaceutical company focused on treatments for cardiovascular and inflammatory diseases, and cancer. During his tenure, he led the company to an FDA approval for their novel protein therapeutic Natrecor.
  • Brewer has also held leadership positions at Genentech, Heartport, and other biotechnology companies, and serves on the boards of Dendreon, Agensys, and Corus Pharma.
  • He holds a BS degree from Virginia Polytechnic Institute and an MBA from Northwestern University.

Statistics:

  • Corgentech's E2F Decoy has completed two phase III clinical trials, both of which have been fully enrolled and have U.S. Food and Drug Administration (FDA) Fast Track Status.
  • The company has an agreement with Bristol-Myers Squibb to jointly develop and commercialize E2F Decoy.
  • Brewer has spent 5 years as the chief executive officer and president of Scios, Inc., and previously served as the chief operating officer at Heartport.
  • E2F Decoy has shown promise in preventing bypass graft failure following CABG and peripheral bypass graft surgery.

Sources:

  • "NewsRx.com & NewsRx.net" (NewsRx.com, 2004 MAY 17)
  • This article was prepared by Health & Medicine Week editors from staff and other reports.

Read more